Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Equity Average (2020 - 2025)

Historic Equity Average for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $148.5 million.

  • Arcutis Biotherapeutics' Equity Average fell 1341.45% to $148.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.5 million, marking a year-over-year decrease of 1341.45%. This contributed to the annual value of $123.1 million for FY2024, which is 1744.86% down from last year.
  • Arcutis Biotherapeutics' Equity Average amounted to $148.5 million in Q3 2025, which was down 1341.45% from $140.8 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Equity Average ranged from a high of $432.7 million in Q2 2021 and a low of $63.6 million during Q3 2023
  • Over the past 5 years, Arcutis Biotherapeutics' median Equity Average value was $174.7 million (recorded in 2023), while the average stood at $212.3 million.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' Equity Average plummeted by 7270.76% in 2023, and later skyrocketed by 16965.45% in 2024.
  • Over the past 5 years, Arcutis Biotherapeutics' Equity Average (Quarter) stood at $330.3 million in 2021, then dropped by 27.29% to $240.2 million in 2022, then crashed by 71.82% to $67.7 million in 2023, then surged by 132.07% to $157.1 million in 2024, then dropped by 5.45% to $148.5 million in 2025.
  • Its Equity Average was $148.5 million in Q3 2025, compared to $140.8 million in Q2 2025 and $150.1 million in Q1 2025.